




INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 : C07D 401/04, 403/04, C07F 7/08, A61K 31/415, 31/44, 31/505	A1	(11) International Publication Number: WO 98/47892 (43) International Publication Date: 29 October 1998 (29.10.98)
(21) International Application Number: PCT/US98/07910 (22) International Filing Date: 17 April 1998 (17.04.98) (30) Priority Data: 60/044,252 24 April 1997 (24.04.97) US (71) Applicant: ORTHO-MCNEIL CORPORATION, INC. [US/US]; U.S. Route #202, P.O. Box 300, Raritan, NJ 08869-0606 (US). (72) Inventors: BEERS, Scott, A.; 11 Kirkride Road, Flemington, NJ 08822 (US). MALLOY, Elizabeth; 8 Canterbury Circle, Flemington, NJ 08822 (US). WACHTER, Michael, P.; 52 North Street, P.O. Box 362, Bloomsbury, NJ 08804 (US). WU, Wei; 149 West End Avenue, Somerville, NJ 08876 (US). (74) Agents: CIAMPORCERO, Audley, A. Jr. et al.; Johnson & Johnson, One Johnson & Johnson Plaza, New Brunswick, NJ 08933 (US).		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i>
(54) Title: SUBSTITUTED IMIDAZOLES USEFUL IN THE TREATMENT OF INFLAMMATORY DISEASES <div style="text-align: center;">(I)</div> (57) Abstract <p>This invention relates to a series of substituted imidazoles of Formula (I), pharmaceutical compositions containing them and intermediates used in their manufacture. The compounds of the invention inhibit the production of a number of inflammatory cytokines, and are useful in the treatment of diseases associated with overproduction of inflammatory cytokines.</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

SUBSTITUTED IMIDAZOLES USEFUL IN THE TREATMENT OF INFLAMMATORY DISEASES

5 This invention relates to a series of substituted imidazoles,
pharmaceutical compositions containing them and intermediates used in their
manufacture. The compounds of the invention inhibit the production of a
number of inflammatory cytokines, particularly, $\text{TNF-}\alpha$, and $\text{IL-1}\beta$. Compounds
of this invention are useful in the treatment of diseases associated with
10 overproduction of inflammatory cytokines, such as rheumatoid arthritis,
inflammatory bowel disease, septic shock, osteoporosis, and osteoarthritis.

BACKGROUND OF THE INVENTION


The inflammatory cytokines, $\text{IL-1}\beta$ and $\text{TNF-}\alpha$ play an important role in a
15 number of inflammatory diseases such as rheumatoid arthritis. C. Dinarello et
al., Inflammatory cytokines: Interleukin-1 and Tumor Necrosis Factor as
Effector Molecules in Autoimmune Diseases *Curr. Opin. Immunol.* **1991**, *3*,
941-48. Arthritis is an inflammatory disease which affects millions of people
and can strike at any joint of the human body. Its symptoms range from mild
20 pain and inflammation in affected joints, to severe and debilitating pain and
inflammation. Although the disease is associated mainly with aging adults, it is
not restricted to adults. The most common arthritis therapy involves the use of
nonsteroidal antiinflammatory drugs (NSAID) to alleviate the symptoms.
However, despite their widespread use, many individuals cannot tolerate the
25 doses necessary to treat the disease over a prolonged period of time. In
addition, NSAIDs merely treat the symptoms of disease without affecting the
underlying cause. Other drugs, such as methotrexate, gold salts, D-
pencillamine, and prednisone are often used when patients fail to respond to
NSAIDs. These drugs also have significant toxicities and their mechanism of
30 action remain unknown.

Receptor antagonists to $\text{IL-1}\beta$ and monoclonal antibodies to $\text{TNF-}\alpha$
have been shown to reduce symptoms of rheumatoid arthritis in small-scale
human clinical trials. In addition to protein based therapies, there are small

molecule agents which inhibit the production of these cytokines and have demonstrated activity in animal arthritis models. J.C. Boehm et al., 1-Substituted 4-Aryl-5-pyridinylimidazoles: A New Class of Cytokine Suppressive Drugs With Low 5-Lipoxygenase and Cyclooxygenase Inhibitory Potency, *J. Med. Chem.*, **1996**, 39, 3929-37. Of these small molecule agents, SB 203580 has proved effective in reducing the production of TNF- α and IL-1 in LPS stimulated human monocyte cell lines with IC₅₀ values of 50 to 100 nM. J. Adams et al., Imidazole Derivatives And Their Use as Cytokine Inhibitor, International Patent application WO 93/14081, July 23, 1993. In addition to this in vitro test, SB 203580 inhibits the production of the inflammatory cytokines in rats and mice at IC₅₀ values of 15 to 25 mg/kg. A.M. Badger, et al, Pharmacological Profile of SB 203580, A Selective Inhibitor of Cytokine Suppressive Binding Protein/p38 Kinase, in Animal Models of Arthritis, Bone Resorption, Endotoxin Shock and Immune Function, *The Journal of Pharmacology and Experimental Therapeutics*, **1996**, 279, 1453-61. Although human data is currently unavailable for SB 203580, monoclonal antibodies to TNF- α have proved efficacious in the treatment of rheumatoid arthritis. M.J. Elliot et al., Treatment of Rheumatoid Arthritis with Chimeric Monoclonal Antibodies to Tumor Necrosis Factor α , *Arthritis Rheum.* 1993 36, 1681-90. Due to SB 203580's oral activity and potency in animal models, researchers have suggested that a compound with this profile has potential as a viable treatment for rheumatoid arthritis. A.M. Badger, et al. Pharmacological Profile of SB 203580, A Selective Inhibitor of Cytokine Suppressive Binding Protein/p38 Kinase, in Animal Models of Arthritis, Bone Resorption, Endotoxin Shock and Immune Function, *The Journal of Pharmacology and Experimental Therapeutics*, **1996**, 279, 1453-61.

SB 203580 and other small molecule agents reduce the production of inflammatory cytokines by inhibiting the activity of a serine/threonin kinase p38 (note other researchers refer to this enzyme as CSBP), at an IC₅₀ of 200 nM. D. Griswold et al., Pharmacology of Cytokine Suppressive Anti-inflammatory Drug Binding Protein (CSPB), A Novel Stress-Induced Kinase, *Pharmacology Communications*, **1996**, 7, 323-29. Although the precise mechanism of this

kinase is unknown, it has been implicated in both the production of TNF- α and the signaling responses associated with the TNF- α receptor.




SB 203580

SUMMARY OF THE INVENTION

The novel compounds of this invention inhibit the in vitro activity of p-38 in the nanomolar range. In addition, the compounds inhibit the in vitro secretion of TNF- α and IL-1 β in the nanomolar range. Animal models demonstrate the inhibition of LPS induced TNF- α , as well as the inhibition of rheumatoid arthritis. With this range of activity the compounds of the invention are useful in the treatment of a variety of cytokine related disorders including: rheumatoid arthritis, inflammatory bowel disease, septic shock osteoporosis, osteoarthritis, neuropathic pain, HIV replication, HIV dementia, viral myocarditis, insulin-dependent diabetes, non-insulin dependent diabetes, periodontal disease, restenosis, alopecia areata, T-cell depletion in HIV infection or AIDS, psoriasis, acute pancreatitis, allograft rejection, allergic inflammation in the lung, atherosclerosis, multiple sclerosis, cachexia, alzheimer's disease, stroke, Crohn's disease, inflammatory bowel disease, ischemia, congestive heart failure, pulmonary fibrosis, hepatitis, glioblastoma, Guillain-Barre Syndrome, and systemic lupus erythematosus.

The invention relates to compounds of the Formula I



I

wherein:

5

R_1 is phenyl, substituted phenyl (where the substituents are selected from the group consisting of C_{1-5} alkyl, halogen, nitro, trifluoromethyl, and nitrile), or heteroaryl where the heteroaryl contains 5 to 6 ring atoms;

10

R_2 is phenyl, substituted phenyl (where the substituents are selected from the group consisting of C_{1-5} alkyl, halogen, nitro, trifluoromethyl, and nitrile), heteroaryl where the heteroaryl contains 5 to 6 ring atoms and is optionally C_{1-4} alkyl substituted;


15

R_3 is hydrogen, SEM, C_{1-5} alkoxycarbonyl, aryloxycarbonyl, aryl C_{1-5} alkyloxycarbonyl, aryl C_{1-5} alkyl, substituted aryl C_{1-5} alkyl (where the aryl substituents are independently selected from one or more members of the group consisting of C_{1-5} alkyl, C_{1-5} alkoxy, halogen, amino, C_{1-5} alkylamino, and di C_{1-5} alkylamino), phthalimido C_{1-5} alkyl, amino C_{1-5} alkyl, diamino C_{1-5} alkyl, succinimido C_{1-5} alkyl, C_{1-5} alkylcarbonyl, arylcarbonyl, C_{1-5} alkylcarbonyl C_{1-5} alkyl, aryloxycarbonyl C_{1-5} alkyl, heteroaryl C_{1-5} alkyl where the heteroaryl contains 5 to 6 ring atoms;

20

25

R_4 is $-(A)-(CH_2)_q-X$ where:




R_5 is selected from the group consisting of hydrogen, C_{1-5} alkyl, phenyl and phenyl C_{1-5} alkyl;

q is 0-9;

X is selected from the group consisting of hydrogen, hydroxy, vinyl, substituted vinyl (where one or more substituents are selected from the group consisting of fluorine, bromine, chlorine and iodine), ethynyl, substituted ethynyl (where the substituents are selected from one or more of the group consisting of fluorine, bromine, chlorine and iodine), C₁₋₅alkyl, substituted C₁₋₅alkyl (where the alkyl substituents are selected from the group consisting of one or more C₁₋₅alkoxy trihaloalkyl, phthalimido and amino), C₃₋₇cycloalkyl, C₁₋₅alkoxy, substituted C₁₋₅alkoxy (where the alkyl substituents are selected from the group consisting of phthalimido and amino), phthalimidooxy, phenoxy, substituted phenoxy (where the phenyl substituents are selected from the group consisting of C₁₋₅alkyl, halogen and C₁₋₅alkoxy), phenyl, substituted phenyl (where the phenyl substituents are selected from the group consisting of C₁₋₅alkyl, halogen and C₁₋₅alkoxy), arylC₁₋₅alkyl, substituted arylC₁₋₅alkyl (where the aryl substituents are selected from the group consisting of C₁₋₅alkyl, halogen and C₁₋₅alkoxy), arylhydroxyC₁₋₅alkyl amino, C₁₋₅alkylamino, diC₁₋₅alkylamino, nitrile, oxime, benzyloxyimino, C₁₋₅alkyloxyimino, phthalimido, succinimido, C₁₋₅alkylcarbonyloxy, phenylcarbonyloxy, substituted phenylcarbonyloxy (where the phenyl substituents are selected from the group consisting of C₁₋₅alkyl, halogen and C₁₋₅alkoxy), phenylC₁₋₅alkylcarbonyloxy, (where the phenyl substituents are selected from the group consisting of C₁₋₅alkyl, halogen and C₁₋₅alkoxy), aminocarbonyloxy, C₁₋₅alkylaminocarbonyloxy, diC₁₋₅alkylaminocarbonyloxy, C₁₋₅alkoxycarbonyloxy, substituted C₁₋₅alkoxycarbonyloxy (where the alkyl substituents are selected from the group consisting of methyl, ethyl, isopropyl and hexyl), phenoxycarbonyloxy, substituted phenoxycarbonyloxy (where the phenyl substituents are selected from the group consisting

of C₁₋₅alkyl, C₁₋₅alkoxy, and halogen), C₁₋₅alkylthio, substituted C₁₋₅alkylthio (where the alkyl substituents are selected from the group consisting of hydroxy and phthalimido), C₁₋₅alkylsulfonyl, phenylsulfonyl, substituted phenylsulfonyl (where the phenyl substituents are selected from the group consisting of bromine, fluorine, chloride, C₁₋₅alkoxy and trifluoromethyl);


with the proviso:



and pharmaceutically acceptable salts thereof.

In addition this invention contemplates pharmaceutical compositions containing compounds of Formula I, and methods of treating cytokine mediated disorders with compounds of Formula I.

Aside from compounds of Formula I, this invention contemplates intermediate compounds of the Formula II. These intermediates are useful in the preparation of compounds of Formula I and are as follows:



wherein:

R₁ is phenyl, substituted phenyl (where the substituents are selected from the group consisting of C₁₋₅alkyl, halogen, nitro, trifluoromethyl, and nitrile), or heteroaryl where the heteroaryl contains 5 to 6 ring atoms;


R₂ is heteroaryl where the heteroaryl contains 5 to 6 ring atoms and is optionally C₁₋₄ alkyl substituted;

R_3 is hydrogen, SEM, C_{1-5} alkoxycarbonyl, aryloxycarbonyl, aryl C_{1-5} alkyloxycarbonyl, aryl C_{1-5} alkyl, substituted aryl C_{1-5} alkyl (where the aryl substituents are independently selected from one or more members of the group consisting of C_{1-5} alkyl, C_{1-5} alkoxy, halogen, amino, C_{1-5} alkylamino, and di C_{1-5} alkylamino), phthalimido C_{1-5} alkyl, aminoc C_{1-5} alkyl, diamino C_{1-5} alkyl, succinimido C_{1-5} alkyl, C_{1-5} alkylcarbonyl, arylcarbonyl, C_{1-5} alkylcarbonyl C_{1-5} alkyl, aryloxycarbonyl C_{1-5} alkyl, heteroaryl C_{1-5} alkyl where the heteroaryl contains 5 to 6 ring atoms;

R_6 is iodine, chlorine, or bromine; and pharmaceutically acceptable salts thereof.

In addition, this invention contemplates methods of preparing compounds of Formula I.

These methods comprise contacting a compound of Formula III



III

wherein

R_1 is phenyl, substituted phenyl (where the substituents are selected from the group consisting of C_{1-5} alkyl, halogen, nitro, trifluoromethyl, and nitrile), or heteroaryl where the heteroaryl contains 5 to 6 ring atoms;


R_2 is phenyl, substituted phenyl (where the substituents are selected from the group consisting of C_{1-5} alkyl, halogen, nitro, trifluoromethyl, and nitrile), heteroaryl where the heteroaryl contains 5 to 6 ring atoms and is optionally C_{1-4} alkyl substituted;

R_3 is hydrogen, SEM, C_{1-5} alkoxycarbonyl, aryloxycarbonyl, aryl C_{1-5} alkyloxycarbonyl, aryl C_{1-5} alkyl, substituted aryl C_{1-5} alkyl (where the aryl substituents are independently selected from one

or more members of the group consisting of C₁₋₅alkyl, C₁₋₅alkoxy, halogen, amino, C₁₋₅alkylamino, and diC₁₋₅alkylamino), phthalimidoC₁₋₅alkyl, aminoC₁₋₅alkyl, diaminoC₁₋₅alkyl, succinimidoC₁₋₅alkyl, C₁₋₅alkylcarbonyl, arylcarbonyl, C₁₋₅alkylcarbonylC₁₋₅alkyl, aryloxy carbonylC₁₋₅alkyl, heteroarylC₁₋₅alkyl where the heteroaryl contains 5 to 6 ring atoms;

R₆ is iodine, chlorine, or bromine;

with a compound of Formula IV



where

q is 0-9

and

X is hydrogen, C₁₋₅alkyl, substituted C₁₋₅alkyl, hydroxy, phenyl, substituted phenyl, amino, C₁₋₅alkylamino, nitrile, vinyl, ethynyl arylC₁₋₅alkyl, succinimido, phthalimidooxy and halogen.

in the presence of a palladium coupling agent, a suitable solvent, and an organic base under reaction conditions which permit the preparation of a compound of Formula I.

DETAILED DESCRIPTION OF THE INVENTION

The terms used in describing the invention are commonly used and known to those skilled in the art. However, the terms that could have other meanings are defined. The term "FCS" represents fetal calf serum, "TCA" represents trichloroacetic acid and the "RPMI" represents the medium from the Roswell Park Memoria Inst. (Sigma cat # R0833). "Independently" means that when there are more than one substituent, the substituents may be different. The term "alkyl" refers to straight, cyclic and branched-chain alkyl groups and "alkoxy" refers O-alkyl where alkyl is as defined supra. The term heteroaryl refers to an aromatic ring of five or six members where at least one member is a heteroatom. Suitable heteroatoms include, nitrogen, oxygen and sulfur. In the case of five-membered rings the heteroaryl will contain one sulfur, oxygen, or nitrogen atom and, in addition, may contain up to three additional nitrogens. With six-membered rings the heteroaryl may contain up to three nitrogens. Examples of such heteroaryls

include, pyridin-2-yl, pyridin-3-yl, pyridin-4-yl, pyrimidin-3-yl, furan-2-yl, furan-3-yl, thiophen-2-yl, thiophen-3-yl, pyridazine, triazine, thiazole, oxazole, pyrazole and the like. "SEM" refers to 2-(trimethylsilyl)ethoxymethyl) and "LDA" refers to lithium diisopropylamide. The symbol "Ph" refers to phenyl, "PHT" refers to phthalimido and the "aryl" includes mono and fused aromatic rings such as phenyl and naphthyl. The symbol C(C) represents an ethynylene group: $\text{---}\{\text{---}\equiv\text{---}\}$, and the symbol (CH)₂ represents a vinylene group: $\text{---}\{\text{---}=\text{---}\}$. The term "reaction conditions" includes physical parameters such as temperature.

As used in this invention the term "cytokine" refers to the proteins TNF- α and IL-1 β . Cytokine related disorders are diseases of humans and other mammals where the overproduction of cytokines causes the symptoms of the disease. The overproduction of the cytokines, TNF- α and IL-1 β has been linked to a number of diseases. These cytokine related disorders include but are not limited to rheumatoid arthritis, inflammatory bowel disease, septic shock osteoporosis, osteoarthritis, neuropathic pain, HIV replication, HIV dementia, viral myocarditis, insulin-dependent diabetes, non-insulin dependent diabetes, periodontal disease, restenosis, alopecia areata, T-cell depletion in HIV infection or AIDS, psoriasis, acute pancreatitis, allograft rejection, allergic inflammation in the lung, atherosclerosis, multiple sclerosis, cachexia, Alzheimer's disease, stroke, Crohn's disease, inflammatory bowel disease, ischemia, congestive heart failure, pulmonary fibrosis, hepatitis, glioblastoma, Guillain-Barre Syndrome, and systemic lupus erythematosus. The term "effective dose" refers to an amount of a compound of Formula I which reduces the amount of TNF α and/or IL-1 β which may be detected in a mammal suffering from a cytokine mediated disorder. In addition, the term "effective dose" refers to an amount of a compound of Formula I which reduces the symptoms of a cytokine related disorder.

The compounds of the invention may be prepared by the following schemes, where some schemes produce more than one embodiment of the invention. In those cases, the choice of scheme is a matter of discretion which is within the capabilities of those skilled in the art.

In order to produce the compounds of the invention where A is ethynylene, Scheme 1 may be used. The starting material for the scheme is a 4,5-disubstituted imidazole of the type 1a. Substituted imidazoles may be prepared following known procedures and the substituents R₁ and R₂ of the compounds of the invention are determined by the substituents of intermediate 1a. Intermediate 1a is treated with a base, such as NaH and an inert solvent such as DMF at room temperature for about 30 min to 1 h. Once anion

formation is complete, an alkylating agent is added such as phenethyl chloride and the reaction mixture is stirred at about 60-100 °C for about 2-4 h to give intermediates 1b₁ and 1b₂. These intermediates are separated at this stage to allow for the formation of final products with one predominate isomer.


- 5 Although the final products may be separated, the separation of 1b₁ and 1b₂ leads to higher yields of products. Alternatively intermediates 1b₁ and 1b₂ can be prepared using the methods described in WO 96/21452, "Certain 1,4,5-Trisubstituted Imidazole Compounds Useful as Cytokine."

- 10 Intermediate 1b₂ is treated with a strong base such as LDA in an inert solvent such as THF at -78 °C for about 30 min. A source of halogen atoms such as iodine or bromine is added to the formed anion and this mixture is allowed to warm to ambient temperature over 30 min to 1 h to give intermediate 1c where W is iodine. Treatment of 1c with a palladium coupling agent such as bis(acetato)bis(triphenylphosphine)palladium II, a substituted
15 ethynyl compound, such as 3-butyne-1-ol and an organic base such as triethylamine in an inert solvent such as methylene chloride at reflux gives compounds of the invention of type 1d. Alternatively, 1c may be treated with other palladium coupling agents. The agents must be palladium II entities and include but are not limited to bis(triphenylphosphine)palladiumdichloride,
20 bis(acetonitrile)chloronitropalladium (II), bis(acetonitrile)-dichloronitropalladium (II), and bis(benzonitrile)dichloropalladium (II). In addition catalytic amounts of copper catalysts, such as copper iodide may be added to increase the speed of the reaction and/or reduce the reaction temperature from reflux to room temperature.

- 25 Although Scheme 1 is used to prepare a compound of the invention where A is ethynylene, n is 1, q is 2, X is hydroxy, R₁ is 1,3-pyrimidin-4-yl, R₂ is 4-chlorophenyl and R₃ is phenethyl, the scheme may be used to prepare other products. For example, to vary R₃, the alkylating agent, may be replaced by either another alkylating agent or an acylating agent. To prepare
30 compounds where R₃ is C₁₋₅alkoxycarbonyl, aryloxycarbonyl, arylC₁₋₅alkoxycarbonyl, C₁₋₅alkylcarbonyl, and arylcarbonyl, an acylating agent replaces the benzyl chloride in Scheme 1. For example, to prepare compounds where R₃ is benzoyl, benzoyl chloride replaces benzyl chloride. If compounds where R₃ is substituted arylC₁₋₅alkyl, aminoC₁₋₅alkyl, substituted
35 aminoC₁₋₅alkyl and C₁₋₅alkyl are desired, benzyl chloride may be replaced with any number of alkylating agents. For example, to prepare compounds where R₃ is a substituted aminoC₁₋₅alkyl, 1-bromo-3-dimethylaminopropane may be used in place of phenethyl chloride.


In order to vary X and q, a variety of known substituted ethynylene compounds may be used. For example if one replaces 3-butyne-1-ol with propargyl chloride, compounds where q is 1 and X is Cl, may be produced. Compounds where q is 0-9 and X is C₁₋₅alkyl, substituted C₁₋₅alkyl, phenyl, substituted phenyl, amino, C₁₋₅alkylamino, nitrile, vinyl, ethynyl aryl, C₁₋₅alkyl, succinimido, phthalimidooxy and halogen may all be prepared in this manner.

Scheme 1



Scheme 2 may be used to prepare compounds of the invention where A is vinylene. Intermediate 1a is the starting material for this scheme and is treated with a base such as NaH and an inert solvent such as DMF at room temperature for about 30 min to 1 h. Once anion formation is complete, 2-(trimethylsilyl)ethoxymethylchloride is added at room temperature and stirred for about 3-5 h to give intermediates 2a₁ and 2a₂. As in Scheme 1, the isomers are separated at this stage. Intermediate 2a₂ is treated with a strong base such as *n*-butyllithium in an inert solvent such as THF at -78 °C for about 1 h. A halogen source such as iodine is added and the mixture is stirred at ambient temperature for about 1 h to give intermediate 2b. Treatment of 2b with a palladium coupling agent such as bis(acetato)bis(triphenylphosphine)palladium II, trimethylsilylacetylene and triethylamine at about 70 °C for 18 to 24 h gives ethynyl intermediate 2c. This intermediate is treated with aqueous HBr in an alcoholic solvent such as EtOH at reflux for about 3-6 h to give a compound of Formula 1 where A is vinyl and X is Br.

Scheme 2





Another method of preparing compounds where A is vinylene, is illustrated by Scheme 3. The starting point for this scheme is the treatment of intermediate 2a₂ with a base such as n-BuLi in an inert solvent such as THF at about -78 °C under an inert atmosphere for about 15-30 min. DMF is added and this mixture is stirred at ambient temperature for about 1-5 h to give the aldehyde intermediate 3a. Treatment of 3a with Wittig reagent formed from triphenylphosphine and carbon tetrabromide, triethylamine and an inert solvent such as methylene chloride gives the vinyl compound 3b. This compound may be treated with an aqueous acid such as HCl at about room temperature over several hours to give the 2-substituted derivative 3c.

Due to the variety of known Wittig reagents, many of the compounds of the invention where A is vinyl may be prepared by Scheme 3. For example, to produce the compounds of the invention where A is vinylene, q is 1 and X is vinyl, the Wittig reagent prepared from triphenylphosphine and allyl bromide replaces the Wittig reagent used in Scheme III. Compounds where q is 1-9 and X is ethynyl, vinyl, substituted vinyl, C₁₋₅alkyl, substituted C₁₋₅alkyl, cycloalkyl, phenyl, araC₁₋₅alkyl, C₁₋₅alkylamino and nitrile may be prepared by this scheme


In addition to compounds where A is vinylene, Scheme 3 may be used to produce compounds where A is ethynylene and X is hydroxy substituted arylalkyl. Treatment of 3c with a base such as n-BuLi in an inert solvent such as THF at -78 °C, followed by treatment with benzaldehyde gives the desired product 3d.

Scheme 3



To produce the compounds of the invention where A is , when R₅ is hydrogen, Scheme 4 may be used. Treatment of intermediate 3a with hydroxylamine in an inert solvent such as MeOH for about 3-6 h at room temperature gives intermediate 4a. The SEM group of 4a may be removed by treatment with an aqueous acid and an alcoholic solvent at reflux for about 4 h to give the desired product 4b. In order to produce the compounds of the invention where R₅ is C₁₋₅alkyl, phenyl, phenylC₁₋₅alkyl, hydroxylamine may be replaced with the known corresponding O-substituted hydroxylamines such as O-benzylhydroxylamine.

Scheme 4




10

The compounds of the invention where X is C₁₋₅alkylthio, substituted C₁₋₅alkylthio, C₁₋₅alkylsulfonyl, phenylsulfonyl and substituted phenylsulfonyl may be produced by Scheme 5. Treatment of 1c with 5-chloro-1-pentyne and a palladium coupling agent as previously described gives compound 5a.

15 Displacement of the chloride with nucleophilic agents such as 2-mercaptoethanol in an inert solvent such as acetonitrile at room temperature gives the thiol 5b. Treatment of 5b with aqueous oxone and an inert solvent

such as MeOH at ambient temperature over 3-6 h gives the sulfone compound 5c.

Scheme 5




- To produce compounds of the invention where X is
- 5 C₁₋₅alkoxycarbonyloxy, compound 1d may be used as illustrated by Scheme 6. Treatment of compound 1d with an acylating agent such as methyl chloroformate at room temperature in an inert solvent and a mild base gives compound 6a. This method may be used to produce compounds of the invention where X is C₁₋₅alkylcarbonyloxy, phenylcarbonyloxy,
 - 10 phenylC₁₋₅alkylcarbonyloxy, aminocarbonyloxy, C₁₋₅alkylaminocarbonyloxy, di

C₁₋₅alkylaminocarbonyloxy, C₁₋₅alkoxycarbonyloxy, substituted C₁₋₅alkoxycarbonyloxy, phenoxycarbonyloxy and substituted phenoxycarbonyloxy by replacing methyl chloroformate with known acylating agents. For example to prepare compounds where X is

- 5 methylaminocarbonyloxy, replace methyl chloroformate with methyl isocyanate.







The compounds where X is halogen may be synthesized using 1d as illustrated by Scheme 6. Treatment of compound 1d with triphenylphosphine and a halogen source such as carbon tetrachloride at room temperature gives compound 6b. Treatment of 6b at room temperature with a nucleophilic agent
10 such as diethyl amine gives compound 6c.


Scheme 6



Although the claimed compounds are useful as inhibitors of TNF- α and IL-1 β , some compounds are more active than others and are either preferred or particularly preferred.

The preferred compounds of Formula I include:





The particularly preferred "R₁"s are phenyl or substituted phenyl where the phenyl substituents are halogen or nitrile.

5 The particularly preferred "R₂"s are pyrid-4-yl, pyrimidin-4-yl and 2-butyl-pyridin-4-yl.

The particularly preferred "R₃"s are hydrogen, (CH₂)₃Ph and (CH₂)₃PHT.

The particularly preferred "A"s are vinylene and ethynylene.

10 The particularly preferred "q"s are 0-6.

The particularly preferred "X"s are hydrogen, hydroxyl, chlorine, nitrile, cyclopentyl, C₁₋₅alkylcarbonyloxy, phenylcarbonyloxy, phenylC₁₋₅alkylcarbonyloxy, aminocarbonyloxy, C₁₋₅alkylaminocarbonyloxy and diC₁₋₅alkylaminocarbonyloxy.

15 Compounds of Formula I may be used in pharmaceutical compositions to treat patients (humans and other primates) with disorders related to the overproduction of inflammatory cytokines, particularly TNF- α . The preferred route is oral administration, however compounds may be administered by intravenous infusion or topical administration. Oral doses range from about 0.05 to 100 mg/kg, daily. Some compounds of the invention may be orally dosed in the range of
20 about 0.05 to about 50 mg/kg daily, while others may be dosed at 0.05 to about 20 mg/kg daily. Infusion doses can range from about 1.0 to 1.0 x 10⁴ μ g/kg/min of inhibitor, admixed with a pharmaceutical carrier over a period ranging from several minutes to several days. For topical administration compounds of Formula I may
25 be mixed with a pharmaceutical carrier at a concentration of about 0.1 to about 10% of drug to vehicle.

The pharmaceutical compositions can be prepared using conventional pharmaceutical excipients and compounding techniques. Oral dosage forms may be elixers, syrups, capsules tablets and the like. Where the typical solid
30 carrier is an inert substance such as lactose, starch, glucose, methyl cellulose, magnesium stearate, dicalcium phosphate, mannitol and the like; and typical

liquid oral excipients include ethanol, glycerol, water and the like. All excipients may be mixed as needed with disintegrants, diluents, granulating agents, lubricants, binders and the like using conventional techniques known to those skilled in the art of preparing dosage forms. Parenteral dosage forms may be prepared using water or another sterile carrier.

Typically the compounds of Formula I are isolated and used as free bases, however the compounds may be isolated and used as their pharmaceutically acceptable salts. Examples of such salts include hydrobromic, hydroiodic, hydrochloric, perchloric, sulfuric, maleic, fumaric, malic, tartatic, citric, benzoic, mandelic, methanesulfonic, hydroethanesulfonic, benzenesulfonic, oxalic, pamoic, 2-naphthalenesulfonic, p-toluenesulfonic, cyclohexanesulfamic and saccharic.

BIOLOGICAL EXAMPLES

The biological activity of the compounds of the invention was demonstrated by in vitro and in vivo assays. As discussed previously, agents which inhibit the activity of the enzyme p38, inhibit the production of the inflammatory cytokines TNF- α , and IL-1 β . Compounds of the invention were measured for their ability to inhibit the activity of p38 by the following in vitro assay.

A solution (38 μ L) of purified recombinant p38 (where the amount of enzyme was determined empirically considering the linear range of the assay and the acceptable signal to noise ratio; 6xHis-p38 expressed in E.coli), myelin basic protein substrate (also determined empirically), a buffer of pH 7.5 (Hepes:25 mM, MgCl₂:10 mM, MnCl₂:10 mM) were added to 92 wells of a 96-well round bottom polypropylene plate. The remaining wells were used for control ("CTRL") and background ("BKG"). The CTRL was prepared with the enzyme, substrate buffer and 2% DMSO, and the BKG was prepared with substrate buffer and 2% DMSO. A solution (12 μ L) of the test compound in DMSO (compounds were diluted to 125 μ M in 10% DMSO/H₂O and assayed at 25 μ M where the final DMSO concentration was 2%) was added to the testing wells. The ATP/³³P-ATP solution (10 μ L: containing 50 μ M unlabeled ATP and 1 μ Ci ³³P-ATP) was added to all wells and the completed plates were mixed and incubated at 30 °C for 30 min. Ice-cold 50 % TCA/10 mM sodium phosphate (60 μ L) were added to each well and the plates were kept on ice for 15 min. The contents of each well were transferred to the wells of a 96-well filterplate (Millipore, MultiScreen-DP) and the filterplate was placed on a vacuum manifold, fitted with a waste collection tray. The wells were washed five times with 10% TCA/10 mM sodium phosphate (200 μ L) under vacuum.

MicroScint-20 scintillant was added, the plates were sealed using Topseal-S sheets and counted in a Packard TopCount scintillation counter using a ^{33}P liquid program with color quench correction, where the output is in color quench-corrected cpm. The % inhibition of the test compounds was calculated by the following formula: % inhibition = $[1 - (\text{sample} - \text{BKG}) / (\text{CTRL} - \text{BKG})] \times 100$.

Although compounds were initially tested at 20 μM , if warranted the compounds were tested at 4-fold increments above and below that concentration. In addition, IC_{50} s were calculated for some compounds using the Deltagraph 4-parameter curve fitting program.

Aside from the enzyme assay, many of the compounds of the invention were tested in an in vitro whole cell assay using peripheral blood mononuclear cells ("PBMC") which were obtained from human blood as follows. Freshly obtained venous blood was anticoagulated with heparin, diluted with an equal volume of phosphate buffered saline ("PBS") and placed in a sterile tube or other container. Aliquots (30 mL) of this mixture were transferred to centrifuge tubes which were underlaid with Ficoll-Hypaque (15 mL). The prepared tubes were centrifuged at 400 x g without braking for 30 min at room temperature. Approximately 1/2 to 2/3 of the platelet layer above the mononuclear cell band was removed with a pipette. The majority of the mononuclear cell layer was carefully removed using a pipette and these PBMCs were diluted with PBS and spun at 600 x g for 15 min. The resulting PBMCs were washed with another portion of PBS and spun at 400 x g for 10 min at room temperature. The recovered pellets were diluted in low endotoxin RPMI / 1% FCS culture medium and gave a cell concentration of $0.5\text{--}2.0 \times 10^6$ PMBC/ mL. A small volume of the suspension was removed for counting on a hemocytometer and the remaining preparation was centrifuged at 200 x g for 15 min at room temperature. The recovered pelleted PMBC were resuspended in RPMI / 1% FCS to a concentration of $1.67 \times 10^6/\text{mL}$.

To run the assay, the PBMC suspension (180 μL) was transferred to duplicate wells of a 96-well flat-bottom microtiter plate and incubated for 1 h at 37 °C. A solution of test compound (10 μL ; prepared at 20 x the desired final concentration) was added to each well and the plate was incubated for 1 h at 37 °C. A solution (10 μL) of LPS in RPMI / 1% FCS (200 ng/mL) was added and the wells were incubated overnight at 37 °C. The supernate (100 μL) was removed from each well and diluted with RPMI / 1% FCS (400 μL). The samples were analyzed for $\text{TNF-}\alpha$ using a commercial ELISA kit (Genzyme).

The $\text{IL-1}\beta$ activity of select compounds of the invention was determined by the following in vitro assay. Plastic-adherent cells were prepared from

PBMC. Briefly, PBMCs were added to the wells of a 96-well plate as above, incubated for 1 h at 37 °C, and the adherent cells prepared by gently resuspending the non-adherent cells with a pipettor, removing and discarding them and gently washing the wells 3 times with 200 µL culture medium.

- 5 Additional culture medium (180 µL) was added to the wells after the final wash. Compound addition, LPS stimulation, incubation and supernate harvest were as for TNF-α. Supernates were assayed for interleukin-1β using a commercial ELISA (Genzyme).

10 Compounds 4 and 36 inhibited the production of IL-1β at IC₅₀s of 7 and 13 nM respectively.

- The ability of the compounds of Formula I to inhibit LPS induced TNF-α production was demonstrated in the following in vivo rodent assays. Mice (BALB / cJ females, Jackson Laboratories) or rats (Lewis males, Charles River) were fasted for 30 min prior to oral dosing with 5-10 mL/kg of test
15 compound at 5-50 mg/kg. Thirty minutes after dosing, the animals were injected intraperitoneally with LPS at 1 mg/kg and returned to their cages for 1 h. Animals were anesthetized by CO₂, exsanguinated by cardiac puncture and whole blood collected (0.1-0.7 mL). The blood was allowed to clot and serum was transferred to a centrifuge tube. This sample was centrifuged, serum was
20 collected, aliquoted and frozen at -80 °C. Samples were tested by commercial ELISAs for TNF-α (Endogen for mouse TNF-α and Biosource for rat TNF-α).

In addition to their in vivo TNF-α activity, a compound of Formula I inhibits polyarthritis in an in vivo rat model as follows. On day 0, male Lewis rats were injected subcutaneously near the base of the tail with 100 µl of a 7.5
25 mg/ml suspension of heat-killed Mycobacterium butyricum in mineral oil.


- Groups of rats were dosed orally, once per day, from day 0 through the end of the experiment with HCl as a negative control, or with 20 or 50 mg/kg of Cpd. 4. As a positive control for inhibition, one group was dosed with HCl on days 0-9, and then with 20 mg/kg (or 50 mg/kg) of cyclosporine (Cys) from day 10
30 through the end of the experiment. Under these conditions, the animals' paws in the negative control group begin to swell on days 11-12. The paw volumes of both rear paws were determined on a mercury plethysmograph on days 8-10, depending on the experiment, and again on days 14, 17, and either 19 or 21. The data were analyzed as the increase in paw volumes compared to the
35 day 8-10 baseline measurements. The data obtained in four experiments is listed in Table A.

TABLE A

Expt. #	Dose (mg/kg)	Ave. % decrease in paw swelling
1	20	79
2	20	4
3	50	71
4	50	20

Select compounds of the invention are listed in Table B. Most compounds were tested for their ability to inhibit p38 and TNF- α , however some compounds were screened in one assay. The IC₅₀s are listed for the majority of compounds and if this calculation is unavailable, the % inhibition is listed for a given concentration. In addition to the biological data, the synthetic schemes used to prepare the compounds are listed. Since imidazoles which are unsubstituted at the 1-position are subject to tautomerization, the substituents listed for R₁ and R₂ are interchangeable when R₃ is hydrogen.

TABLE B




	Cpd.	R ₁	R ₂	R ₃	R ₄	p-38	TNF- α	Scheme
						IC ₅₀ μ m	IC ₅₀ nm	
	4	4-F-Ph	4-pyr	(CH ₂) ₃ Ph	C(C)(CH ₂) ₂ OH	0.65	3.0	1
	8	4-F-Ph	4-pyr	H	(CH ₂) ₂ Cl	1.5		2
	10	4-pyr	4-F-Ph	SEM	(CH ₂) ₂ Br ₂	16% @ 5 μ m		3
15	11	4-F-Ph	4-pyr	H	C(C)CH(OH)-Ph		400	3
20	13	4-F-Ph	4-pyr	H	CH(N)OH		45	4
	14	4-F-Ph	4-pyr	(CH ₂) ₃ Ph	C(C)(CH ₂) ₃ Cl		4	6
	15	4-F-Ph	4-pyr	(CH ₂) ₃ Ph	C(C)(CH ₂) ₂ - -OC(O)NHPH		38	6
25	16	4-F-Ph	4-pyr	(CH ₂) ₃ Ph	C(C)(CH ₂) ₂ Cl		6	6
	17	4-F-Ph	4-pyr	(CH ₂) ₃ Ph	C(C)(CH ₂) ₂ N(CH ₃) ₂		3	
	18	4-F-Ph	4-pyr	SEM	(CH ₂) ₂ Br ₂		1500	3
	19	4-F-Ph	4-pyr	H	C(C)(CH ₂) ₃ OH		85	1
	20	4-pyr	4-F-Ph	SEM	C(C)(CH ₂) ₂ OH		>10,000	1
30	21	4-F-Ph	4-pyr	H	C(C)(CH ₂) ₂ OH		80	1

	22	4-F-Ph	4-pyr	H	C(C)(CH ₂) ₃ PHT		700	6
	23	4-pyr	4-F-Ph	SEM	C(C)(CH ₂) ₄ OH		>2,000	1
	24	4-F-Ph	4-pyr	H	C(C)(CH ₂) ₄ OH		100	1
	25	4-pyr	4-F-Ph	SEM	C(C)(CH ₂) ₃ CN		>2,000	1
5	26	4-pyr	4-F-Ph	SEM	C(C)(CH ₂) ₂ CH ₃		>2,000	1
	27	4-pyr	4-F-Ph	H	C(C)(CH ₂) ₃ CN		55	1
	28	4-pyr	4-F-Ph	H	C(C)(CH ₂) ₂ CH ₃		80	1
	29	4-pyr	4-F-Ph	H	C(C)(CH ₂) ₃ PHT		200	1
	30	4-F-Ph	4-pyr	H	C(C)H		150	6
10	31	4-F-Ph	4-pyr	H	C(C)Br		250	1
	32	4-F-Ph	4-pyr	H	CH(N)OCH ₂ Ph		80	2
	33	4-F-Ph	4-pyr	H	CH(N)O- CH ₂ (4-NO ₂ Ph)		150	4
	34	4-F-Ph	4-pyr	(CH ₂) ₃ Ph	C(C)(CH ₂) ₂ CH ₃		10.0	1
15	35	4-F-Ph	4-pyr	(CH ₂) ₃ Ph	C(C)(CH ₂) ₃ OH	99% @ 20 μm	8.0	1
	36	4-F-Ph	4-pyr	(CH ₂) ₃ Ph	C(C)(CH ₂) ₃ CN	1.5	9.0	1
	37	4-F-Ph	4-pyr	(CH ₂) ₃ PHT	C(C)(CH ₂) ₂ OH		160	1
	38	4-F-Ph	4-pyr	(CH ₂) ₃ Ph	C(C)(CH ₂) ₃ Ph		40	1
	39	4-F-Ph	4-pyr	(CH ₂) ₃ Ph	C(C)(CH ₂) ₃ S(CH ₂) ₃ CH ₃		200	5
20	40	4-F-Ph	4-pyr	(CH ₂) ₃ Ph	C(C)(CH ₂) ₃ -SO ₂ (CH ₂) ₃ CH ₃		6.5	5
	41	4-F-Ph	4-pyr	(CH ₂) ₃ Ph	C(C)CH ₂ cyclopentyl		28	1
	42	4-F-Ph	4-pyr	(CH ₂) ₃ Ph	C(C)(CH ₂) ₅ CH ₃		90	1
25	43	4-F-Ph	4-pyr	(CH ₂) ₃ Ph	C(C)(CH ₂) ₄ OH	98% @ 20 μm	5.2	1
	44	4-F-Ph	4-pyr	H	(CH ₂) ₂ Br ₂	93% @ 20 μm	200	2
	45	4-F-Ph	4-pyr	SEM	C(C)(CH ₂) ₃ - -N-Succinimide		650	1
	46	4-F-Ph	4-pyr	H	(CH ₂) ₂ CN		250	1
30	47	4-F-Ph	4-pyr	(CH ₂) ₃ Ph	C(C)CH ₂ OH		7.2	1
	48	4-F-Ph	4-pyr	(CH ₂) ₃ Ph	C(C)CH ₂ OPHT		85	1
	49	4-F-Ph	4-pyr	(CH ₂) ₃ Ph	C(C)(CH ₂) ₂ OCH ₃		3	6
	50	4-F-Ph	4-pyr	(CH ₂) ₃ Ph	C(C)(CH ₂) ₂ OCOPh		2	6
	51	4-F-Ph	4-pyr	(CH ₂) ₃ Ph	C(C)(CH ₂) ₂ H		5.5	1
35	52	4-F-Ph	4-pyr	(CH ₂) ₃ Ph	C(C)(CH ₂) ₂ OCOCH ₃		2.6	6

The in vivo test results for select compounds of the invention are listed in Table C. The compounds were tested for their ability to inhibit TNF- α production in mice and/or rats and the data is listed as % inhibition at 25 mg/kg.

TABLE C




Cpd.	R ₁	R ₂	R ₃	R ₄	% Inhibition TNF- α	
					Mice	Rats
4	4-F-Ph	4-pyr	(CH ₂) ₃ Ph	C(C)(CH ₂) ₂ OH	49.6	91
19	4-F-Ph	4-pyr	H	C(C)(CH ₂) ₃ OH	29	
24	4-F-Ph	4-pyr	H	C(C)(CH ₂) ₄ OH	73	
26	4-pyr	4-F-Ph	SEM	C(C)(CH ₂) ₂ CH ₃	0	
27	4-pyr	4-F-Ph	H	C(C)(CH ₂) ₃ CN	95	
28	4-pyr	4-F-Ph	H	C(C)(CH ₂) ₂ CH ₃	88	
34	4-F-Ph	4-pyr	(CH ₂) ₃ Ph	C(C)(CH ₂) ₂ CH ₃	53	
35	4-F-Ph	4-pyr	(CH ₂) ₃ Ph	C(C)(CH ₂) ₃ OH	68	
36	4-F-Ph	4-pyr	(CH ₂) ₃ Ph	C(C)(CH ₂) ₃ CN	69.3	
43	4-F-Ph	4-pyr	(CH ₂) ₃ Ph	C(C)(CH ₂) ₄ OH	53	

PREPARATIVE EXAMPLES

In order to illustrate the invention the following examples are included. These examples do not limit the invention. They are only meant to suggest a method of practicing the invention. Those skilled in the art may find other methods of practicing the invention, which are obvious to them. However those methods are deemed to be within the scope of this invention.

Example 1



5(4)-(4-Fluorophenyl)- 4(5)-(4-pyridyl)imidazole


Cpd. 1

A solution of selenium dioxide (4.82 g, 43.4 mmol) in H₂O (20 mL) was added to a solution of 1-(4-fluorophenyl)-2-(4-pyridyl)-2-ethanone (9.33 g, 43.4 mmol) in dioxane (100 mL) and the resulting mixture was heated at reflux for 2 h. This mixture was concentrated in vacuo, triturated with ethyl acetate and filtered.

5 The residue was purified by column chromatography using ethyl acetate/ hexane (1:1) as an eluent to give 1-(4-fluorophenyl)-2-(4-pyridyl)-1,2-ethandione. A mixture of ammonium acetate (25.25 g, 0.328 mol) and hexamethylenetetraamine (9.18 g, 65.5 mmol) was added to a solution of the isolated dione dissolved in acetic acid (150 mL). This mixture was stirred at 80 °C for 2 h, poured into

10 concentrated ammonium hydroxide (200 mL) and the resulting precipitate was filtered, washed with H₂O and dried to give the title compound as a solid: mp 242-44.3 °C; MS 240 (MH⁺).


Example 2



2a

4-(4-Fluorophenyl)-1-(3-phenylpropyl)-5-(4-pyridyl)imidazole

Cpd. 2a



2b

5-(4-Fluorophenyl)-1-(3-phenylpropyl)-4-(4-pyridyl)imidazole


Cpd. 2b

60% Sodium hydride (1.32 g, 33 mmol) was added to a mixture of compound 1 (7.15 g, 29.9 mmol) in DMF (70 mL) and stirred for 30 min.

3-Bromophenylpropane ((5.05 mL, 33 mmol) was added and the reaction mixture was stirred under N₂ at 60 °C for 2h. The mixture was poured into H₂O and

25 extracted with several portions of ethyl acetate. The combined organic layer was washed with H₂O, concentrated in vacuo and purified by column chromatography on silica gel using ethyl acetate as an eluent. Compound 2a is the more polar compound and was isolated as a solid: mp 70-74 °C; MS 358 (MH⁺). Compound 2b was the least polar compound and was isolated as a solid: mp 107.5-112.5 °C.


Example 3



4-(4-Fluorophenyl)-2-iodo-1-(3-phenylpropyl)-5-(4-pyridyl)imidazole
Cpd. 3

- 5 2M Lithium diisopropylamide/THF (17 mL) was added to a solution of compound 2a (9.69 g, 27.1 mmol) at -78 °C and this mixture was stirred at -78 °C for 15 minutes. Iodine (10.0 g, 39.4 mmol) was added and the resulting mixture was allowed to warm up to ambient temperature over 30 min. Aqueous sodium sulfite and ethyl acetate were added and the organic layer was separated, washed
10 with water and concentrated in vacuo. The residue was purified by column chromatography on silica gel and eluted with ethyl acetate : hexane (1:1) to give compound 3 as a solid: mp 117-19 °C; MS 484 (MH⁺).

Example 4



4-(4-Fluorophenyl)-2-(4-hydroxybutyn-1-yl)-1-(3-phenylpropyl)-
5-(4-pyridyl)imidazole
Cpd. 4

- 15 Triethylamine (80 mL), bis(acetato)bis(triphenylphosphine)palladium II ((0.71 g, 0.95 mmol) and 3-butyne-1-ol (2.90mL, 37.6 mmol) were added to a
20 solution of compound 3 (9.10 g, 18.8 mmol) in methylene chloride (40 mL). The reaction mixture was stirred at reflux for 4 h, concentrated in vacuo and partitioned between H₂O and ethyl acetate. The organic layer was concentrated in vacuo and


purified by column chromatography using ethyl acetate as an eluent to give compound 4 as a solid: mp 125-26.5 °C; MS 426 (MH⁺).

Aside from compound 4, additional compounds of Formula I were prepared by the method of this example. Appropriately substituted ethynyl derivatives were used in place of 3-butyn-1-ol to give the compounds listed in Table D with their found mass spectrum data.


Table D

Cpd.	R ₁	R ₂	R ₃	R ₄	(MH ⁺)
34	4-F-Ph	4-pyr	(CH ₂) ₃ Ph	C(C)(CH ₂) ₂ CH ₃	424
35	4-F-Ph	4-pyr	(CH ₂) ₃ Ph	C(C)(CH ₂) ₃ OH	440
36	4-F-Ph	4-pyr	(CH ₂) ₃ Ph	C(C)(CH ₂) ₃ CN	449
38	4-F-Ph	4-pyr	(CH ₂) ₃ Ph	C(C)(CH ₂) ₃ Ph	500
39	4-F-Ph	4-pyr	(CH ₂) ₃ Ph	C(C)(CH ₂ S(CH ₂)CH ₃	512
41	4-F-Ph	4-pyr	(CH ₂) ₃ Ph	C(C)(CH ₂) ₅ CH ₃	466
42	4-F-Ph	4-pyr	(CH ₂) ₃ Ph	C(C)(CH ₂) ₄ OH	454
43	4-F-Ph	4-pyr	(CH ₂) ₃ Ph	C(C)CH ₂ cyclopentyl	464
47	4-F-Ph	4-pyr	(CH ₂) ₃ Ph	C(C)(CH ₂)OH	412
48	4-F-Ph	4-pyr	(CH ₂) ₃ Ph	C(C)(CH ₂)OPHT	557

Example 5



Cpd. 5a



Cpd. 5b

4-(4-Fluorophenyl)-5-(4-pyridyl)-1-(2-(trimethylsilyl)ethoxymethyl)-imidazole Cpd. 5a


5-(4-Fluorophenyl)-4-(4-pyridyl)-1-(2-(trimethylsilyl)ethoxymethyl)-imidazole Cpd. 5b

60% Sodium Hydride (0.92 g, 23 mmol) was added to a stirred solution of 5(4)-(4-fluorophenyl)-4(5)-(4-pyridyl)-imidazole (5.50 g, 23 mmol) in DMF under N₂. 2-(Trimethylsilyl)ethoxymethyl chloride (4.07 mL, 23 mmol) was added after 15 min and the resulting mixture was stirred for 3 h, poured into H₂O, dried (MgSO₄) and concentrated in vacuo. The resulting oil was purified by column

chromatography on silica gel using ethyl acetate as an eluent. The first isomer crystallized to give compound 5a: mp 111-13 °C; MS 370 (MH⁺). The second isomer crystallized to give compound 5b: mp 62-64 °C; MS 370 (MH⁺).

5

Example 6



5-(4-Fluorophenyl)-2-iodo-4-(4-pyridyl)-1-(2-(trimethylsilyl)ethoxymethyl)-imidazole


Cpd. 6

10

2N *n*-Butyllithium/THF (3.2 mL) was added to a stirred solution of compound 5b (2.35 g, 6.40 mmol) in ether (150 mL) at -78 °C. After 1h, iodine (2.16 g, 8.50 mmol) was added and the reaction mixture was stirred at ambient temperature for 1h. Aqueous sodium sulfite (100 mL) was added and the resulting organic layer was washed with H₂O, dried (MgSO₄) and purified by column chromatography to give compound 6 as an oil: MS 496 (MH⁺).

15

Example 7



5-(4-Fluorophenyl)-4-(4-pyridyl)-2-(trimethylsilyl)ethynyl-1-(2-(trimethylsilyl)ethoxymethyl)-imidazole

Cpd. 7

20


Trimethylsilylacetylene (0.31 mL), bis(acetato)bis(triphenylphosphine)-palladium (II) (5 mol %) were added to a solution of compound 2 (0.60 g, 1.20 mmol) in triethylamine (15 mL) and the resulting mixture was stirred at 70 °C for 18 h. The resulting mixture was cooled to room temperature, and the solid filtrate

25

was isolated. This solid was washed with triethylamine and the combined organic layers were concentrated in vacuo. The residue was purified by column chromatography using ethyl acetate:hexane (1:1) as an eluent to give compound 7 as a solid: mp 128.3-129 °C; MS 466 (MH⁺).

5

Example 8




2-(2-Chlorovinyl)-5-(4-fluorophenyl)-4-(4-pyridyl)-imidazole

Cpd. 8

10 3N HCl was added to a solution of compound 7 in ethanol and the mixture was heated at reflux for 5 h. The resulting reaction brew was concentrated in vacuo, neutralized with sodium bicarbonate and extracted with ethyl acetate. The organic layer was concentrated in vacuo and purified by column chromatography using ethyl acetate as an eluent to give compound 8 as a solid: mp 185-87 °C; MS

15 300 (MH⁺).

Example 9



5-(4-Fluorophenyl)-4-(4-pyridyl)-1-(2-(trimethylsilyl)ethoxymethyl)-imidazole-2-carboxaldehyde

Cpd. 9


20

1.6 N n-BuLi (13 mL, 21 mmol) was added to a stirred solution of compound 5b (7.10 g, 19.2 mmol) in THF at -78 °C. After 15 min, DMF (2.0 mL, 26 mmol) was added and the mixture was stirred at ambient temperature for 1 h and

25 quenched with water. This mixture was extracted with ethyl acetate and the combined organic extracts were concentrated in vacuo. The residue was purified

by column chromatography on silica gel using ethyl acetate : hexanes (1:1) to give compound 9 as a solid: mp 42-45 °C; MS 398 (MH⁺).

Example 10




5

2-[2,2-Dibromoethylene-1-yl]-5-(4-fluorophenyl)-4-(4-pyridyl)-
1-(2-(trimethylsilyl)ethoxymethyl)imidazole

Cpd. 10

Triphenyl phosphine (13.40 g, 51.1 mmol) was dissolved in methylene
10 chloride (300 mL) and cooled to -10 °C. A solution of carbon tetrabromide (8.50 g,
25.6 mmol) was added dropwise, followed by a solution of compound 9 (6.85 g,
17.2 mmol) and triethylamine (2.79 mL, 20 mmol) in methylene chloride. This
mixture was stirred for 30 min, poured into ether (500 mL) and filtered. The filtrate
was concentrated in vacuo, purified by column chromatography on silica gel using
15 ethyl acetate : hexane (1:1) as an eluent to give compound 10 as a solid: mp 128-
31 °C; MS 554 (MH⁺).

Example 11



20


5(4)-(4-Fluorophenyl)-2-(3-hydroxy-3-phenyl-propyn-1-yl)-
4(5)-(4-pyridyl)imidazole

Cpd. 11

1.6N *n*-Butyllithium (5.0 mL, 8.0 mmol) was added to a stirred solution of
compound 10 (2.20 g, 3.80 mmol) in THF (50 mL) at -78 °C. After 30 min
25 benzaldehyde (0.40 mL, 3.94 mmol) was added and the mixture was allowed to
stir at ambient temperature for 30 min. Water was added and the resulting
organic layer was concentrated in vacuo and dissolved in MeOH (20 mL) and 1N

HCl (20 mL). This mixture was stirred for 2 h at 50 °C and the resulting mixture was neutralized with sodium bicarbonate and extracted with ethyl acetate. The combined organic layer was dried (MgSO₄) and purified on silica gel using ethyl acetate as an eluent to give compound 11 as a solid: mp 193-94 °C; MS 370

5 (MH⁺).




5-(4-Fluorophenyl)- 4-(4-pyridyl)- 1-(2-(trimethylsilyl)ethoxymethyl)-
2-oximinoimidazole

10

Cpd. 12

A solution of hydroxylamine hydrochloride (0.09 g, 1.3 mmol), sodium bicarbonate (0.11 g, 1.3 mmol) and H₂O (5 mL) was added to a stirred solution of compound 9 (0.50 g, 1.2 mmol) in MeOH (5 mL) at room temperature. This mixture was stirred for 3 h and poured into H₂O. The solid precipitate was filtered and dried in vacuo to give the title compound as a solid: mp 212-13 °C; MS 413 (MH⁺).

15



20


5-(4-Fluorophenyl)- 4-(4-pyridyl)-2-imidazoleoxime

Cpd. 13

0.5 M HCl (3 mL) was added to a solution of compound 12 in MeOH (5 mL). This mixture was heated at reflux for 2 h, neutralized with sodium bicarbonate and the resulting precipitate was filtered. This solid was recrystallized from MeOH/H₂O to give the title compound as a solid; mp 318-20 °C; MS 283 (MH⁺).

25

Example 14



2-(5-Chloropentyn-1-yl)-4-(4-fluorophenyl)-1-(3-phenylpropyl)-
5-(4-pyridyl)imidazole


5

Cpd. 14

Triethylamine (50 mL), bis(acetato)bis(triphenylphosphine)palladium II (0.71 g, 0.95 mmol) and 5-chloro-1-pentyne (0.71 mL, 6.70 mmol) and compound 3 (1.62 g, 3.35 mmol) were stirred at reflux for 16 h. Ethyl acetate was added and the solid precipitates were removed by filtration. The filtrate layer concentrated in vacuo and purified by column chromatography using ethyl acetate-hexane (1:2) as an eluent to give compound 14 as a solid: mp 102-104 °C.

10

Example 15



4-(4-Fluorophenyl)-2-(4-N-phenylcarbamoyloxybutyn-1-yl)-1-(3-phenylpropyl)-
5-(4-pyridyl)imidazole


15

Cpd 15

Phenylisocyanate (11 mL, 1.0 mmol) was added to a stirred solution of compound 4 (200 mg, 0.50 mmol) in pyridine. The mixture was stirred for 4 h and poured into ice. The solid precipitate was washed with water and dried to give compound 15 as a solid: mp 120-24 °C.

20

Example 16




2-(4-Chlorobutyn-1-yl)-4-(4-fluorophenyl)-1-(3-phenylpropyl)-
5-(4-pyridyl)imidazole

Cpd. 16

5

Triphenylphosphine (1.11 g, 4.23 mmol) and carbon tetrachloride (0.41 mL, 4.23 mmol) were added to a solution of compound 4 (0.9 g, 2.12 mmol) at room temperature. The mixture was stirred for 22 h, concentrated in vacuo and purified by column chromatography using ethyl acetate : hexane (1:1) as an eluent to give
10 the title compound as a solid: mp 132-34 °C.

Example 17



2-(4-Dimethylaminobutyn-1-yl)-4-(4-fluorophenyl)-1-(3-phenylpropyl)-
5-(4-pyridyl)imidazole


15

Cpd. 17

A solution of compound 16 (208 mg, 0.47 mmol) in 2N dimethylamine/MeOH (10 mL) was stirred for 18 h at room temperature and concentrated in vacuo. The residue was purified by column chromatography
20 using methylene chloride: MeOH (19:1) as an eluent to give the title compound as a solid: mp 115-17 °C.

What is claimed is

1. A compound of Formula I




5 wherein:

R_1 is phenyl, substituted phenyl (where the substituents are selected from the group consisting of C_{1-5} alkyl, halogen, nitro, trifluoromethyl, and nitrile), or heteroaryl where the heteroaryl contains 5 to 6 ring atoms;

R_2 is phenyl, substituted phenyl (where the substituents are selected from the group consisting of C_{1-5} alkyl, halogen, nitro, trifluoromethyl, and nitrile), heteroaryl where the heteroaryl contains 5 to 6 ring atoms and is optionally C_{1-4} alkyl substituted;

R_3 is hydrogen, SEM, C_{1-5} alkoxycarbonyl, aryloxycarbonyl, aryl C_{1-5} alkyloxycarbonyl, aryl C_{1-5} alkyl, substituted aryl C_{1-5} alkyl (where the aryl substituents are independently selected from one or more members of the group consisting of C_{1-5} alkyl, C_{1-5} alkoxy, halogen, amino, C_{1-5} alkylamino, and di C_{1-5} alkylamino), phthalimido C_{1-5} alkyl, amino C_{1-5} alkyl, diamino C_{1-5} alkyl, succinimido C_{1-5} alkyl, C_{1-5} alkylcarbonyl, arylcarbonyl, C_{1-5} alkylcarbonyl C_{1-5} alkyl, aryloxycarbonyl C_{1-5} alkyl, heteroaryl C_{1-5} alkyl where the heteroaryl contains 5 to 6 ring atoms;

R_4 is (A)-(CH₂)₄-X where:




R₅ is selected from the group consisting of hydrogen, C₁₋₅alkyl, phenyl and phenylC₁₋₅alkyl;

q is 0-9;

X is selected from the group consisting of hydrogen, hydroxy, vinyl, substituted vinyl (where one or more substituents are selected from the group consisting of fluorine, bromine, chlorine and iodine), ethynyl, substituted ethynyl (where the substituents are selected from one or more of the group consisting of fluorine, bromine, chlorine and iodine), C₁₋₅alkyl, substituted C₁₋₅alkyl (where the alkyl substituents are selected from the group consisting of one or more C₁₋₅alkoxy trihaloalkyl, phthalimido and amino), C₃₋₇cycloalkyl, C₁₋₅alkoxy, substituted C₁₋₅alkoxy (where the alkyl substituents are selected from the group consisting of phthalimido and amino), phthalimidooxy, phenoxy, substituted phenoxy (where the phenyl substituents are selected from the group consisting of C₁₋₅alkyl, halogen and C₁₋₅alkoxy), phenyl, substituted phenyl (where the phenyl substituents are selected from the group consisting of C₁₋₅alkyl, halogen and C₁₋₅alkoxy), arylC₁₋₅alkyl, substituted arylC₁₋₅alkyl (where the aryl substituents are selected from the group consisting of C₁₋₅alkyl, halogen and C₁₋₅alkoxy), arylhydroxyC₁₋₅alkyl amino, C₁₋₅alkylamino, diC₁₋₅alkylamino, nitrile, oxime, benzyloxyimino, C₁₋₅alkyloxyimino, phthalimido, succinimido, C₁₋₅alkylcarbonyloxy, phenylcarbonyloxy, substituted phenylcarbonyloxy (where the phenyl substituents are selected from the group consisting of C₁₋₅alkyl, halogen and C₁₋₅alkoxy), phenylC₁₋₅alkylcarbonyloxy, (where the phenyl substituents are selected from the group consisting of C₁₋₅alkyl, halogen and C₁₋₅alkoxy), aminocarbonyloxy, C₁₋₅alkylaminocarbonyloxy, diC₁₋₅alkylaminocarbonyloxy, C₁₋₅alkoxycarbonyloxy, substituted C₁₋₅alkoxycarbonyloxy (where the alkyl substituents are selected from the group consisting of methyl, ethyl, isopropyl and hexyl),

phenoxy carbonyloxy, substituted phenoxy carbonyloxy (where the phenyl substituents are selected from the group consisting of C₁₋₅alkyl, C₁₋₅alkoxy, and halogen), C₁₋₅alkylthio, substituted C₁₋₅alkylthio (where the alkyl substituents are selected from the group consisting of hydroxy and phthalimido), C₁₋₅alkylsulfonyl, phenylsulfonyl, substituted phenylsulfonyl (where the phenyl substituents are selected from the group consisting of bromine, fluorine, chloride, C₁₋₅alkoxy and trifluoromethyl);

with the proviso:



, q is 0 and X is H, R₃ may not be SEM;

and pharmaceutically acceptable salts thereof.

2. The compound of claim 1 where R₁ is substituted phenyl and R₂ is pyridin-2-yl, pyridin-3-yl, pyridin-4-yl, pyrimidin-3-yl, furan-2-yl, furan-3-yl, thiophen-2-yl, thiophen-3-yl, pyridazine, triazine, thiazole, and oxazole, pyrazole.
3. The compound of claim 2 where R₁ is 4-fluorophenyl and R₂ is pyridin-4-yl.
4. The compound of claim 3 where R₃ is hydrogen, arylC₁₋₅alkyl, or substituted arylC₁₋₅alkyl.
5. The compound of claim 4 where R₃ is hydrogen or phenylC₁₋₅alkyl.
6. The compound of claim 5 where A is ethynylene and q is 0-5.
7. The compound of claim 6 where X is succinimido, hydroxy, methyl, phenyl, C₁₋₅alkylsulfonyl, C₃₋₆cycloalkyl, C₁₋₅alkylcarbonyloxy, C₁₋₅alkoxy, phenylcarbonyloxy, C₁₋₅alkylamino, diC₁₋₅alkylamino, or nitrile.
8. A compound and pharmaceutically acceptable salts thereof selected from the group consisting of 4-(4-fluorophenyl)-2-(4-hydroxybutyn-1-yl)-1-(3-phenylpropyl)-5-(4-pyridinyl)imidazole, 4-(4-fluorophenyl)-2-(3-hydroxypropyn-1-yl)-1-(3-phenylpropyl)-5-(4-pyridinyl)imidazole, 4-(4-

fluorophenyl)-2-(5-hydroxypentyn-1-yl)-1-(3-phenylpropyl)-5-(4-pyridinyl)imidazole, and 4-(4-fluorophenyl)-2-(6-hydroxyhexyn-1-yl)-1-(3-phenylpropyl)-5-(4-pyridinyl)imidazole.

5 9. A compound 4-(4-fluorophenyl)-2-(4-hydroxybutyn-1-yl)-1-(3-phenylpropyl)-5-(4-pyridinyl)imidazole and pharmaceutically acceptable salts thereof.

10 10. A compound and pharmaceutically acceptable salts thereof selected from the group consisting of 4-(4-fluorophenyl)-2-(5-cyanopentyn-1-yl)-1-(3-phenylpropyl)-5-(4-pyridinyl)imidazole, 4-(4-fluorophenyl)-2-(4-dimethylaminobutyn-1-yl)-1-(3-phenylpropyl)-5-(4-pyridinyl)imidazole, 4-(4-fluorophenyl)-2-(4-(phenylcarbonyloxy)butyn-1-yl)-1-(3-phenylpropyl)-5-(4-pyridinyl)imidazole, 4-(4-fluorophenyl)-2-(4-(methylcarbonyloxy)butyn-1-yl)-1-(3-phenylpropyl)-5-(4-pyridinyl)imidazole, 4-(4-fluorophenyl)-2-(3-cyclopentylpropyn-1-yl)-1-(3-phenylpropyl)-5-(4-pyridinyl)imidazole, and 4-(4-fluorophenyl)-2-(5-(butylsulfonyl)pentyn-1-yl)-1-(3-phenylpropyl)-5-(4-pyridinyl)imidazole.


20 11. A compound and pharmaceutically acceptable salts thereof selected from the group consisting of 4-(4-fluorophenyl)-2-(octyn-1-yl)-1-(3-phenylpropyl)-5-(4-pyridinyl)imidazole, 4-(4-fluorophenyl)-2-(5-butylthiopentyn-1-yl)-1-(3-phenylpropyl)-5-(4-pyridinyl)imidazole, 4-(4-fluorophenyl)-2-(5-phenylpentyn-1-yl)-1-(3-phenylpropyl)-5-(4-pyridinyl)imidazole, 4-(4-fluorophenyl)-2-(5-chloropentyn-1-yl)-1-(3-phenylpropyl)-5-(4-pyridinyl)imidazole, 4-(4-fluorophenyl)-2-(5-hydroxypentyn-1-yl)-1-(3-phthalimidopropyl)-5-(4-pyridinyl)imidazole, 4-(4-fluorophenyl)-2-(pentyn-1-yl)-1-(3-phenylpropyl)-5-(4-pyridinyl)imidazole, and 4-(4-fluorophenyl)-2-(5-N-succinimidopentyn-1-yl)-1-(3-phenylpropyl)-5-(4-pyridinyl)imidazole.

30 12. The compound of claim 1 where R₁ is phenyl and R₂ is selected from the group consisting of 3-pyrimidinyl, 2-furanyl, 3-furanyl, 2-thiophenyl, and 3-thiophenyl.

35 13. The compound of claim 12 where R₂ is 3-pyrimidinyl.

14. A pharmaceutical composition comprising a compound according to claim 1 and a pharmaceutically acceptable carrier or diluent.

15. A pharmaceutical composition comprising a compound according to claim 7 and a pharmaceutically acceptable carrier or diluent.
16. A pharmaceutical composition comprising a compound according to claim 8 and a pharmaceutically acceptable carrier or diluent.
17. A pharmaceutical composition comprising a compound according to claim 9 and a pharmaceutically acceptable carrier or diluent.
18. A method of treating a cytokine mediated disease comprising administering a compound of claim 1 to a mammal at an effective dose.
19. A method of treating a cytokine mediated disease comprising administering a composition of claim 14 to a mammal at an effective dose.
20. The method of claim 18 where the compound is administered orally and an effective dose is 0.1-100 mg/kg daily.
21. The method of claim 20 where the dose is 0.1-50 mg/kg daily.
22. A method of treating arthritis comprising administering an effective dose of a compound of Claim I.
23. A compound of Formula II



II

wherein:

R₁ is phenyl, substituted phenyl (where the substituents are selected from the group consisting of C₁₋₅alkyl, halogen, nitro, trifluoromethyl, and nitrile), or heteroaryl where the heteroaryl contains 5 to 6 ring atoms;

R₂ is heteroaryl where the heteroaryl contains 5 to 6 ring atoms and is optionally C₁₋₄ alkyl substituted;

5 R₃ is hydrogen, SEM, C₁₋₅alkoxycarbonyl, aryloxycarbonyl, arylC₁₋₅alkyloxycarbonyl, arylC₁₋₅alkyl, substituted arylC₁₋₅alkyl (where the aryl substituents are independently selected from one or more members of the group consisting of C₁₋₅alkyl, C₁₋₅alkoxy, halogen, amino, C₁₋₅alkylamino, and diC₁₋₅alkylamino), phthalimidoC₁₋₅alkyl, aminoC₁₋₅alkyl, diaminoC₁₋₅alkyl, 10 succinimidoC₁₋₅alkyl, C₁₋₅alkylcarbonyl, arylcarbonyl, C₁₋₅alkylcarbonylC₁₋₅alkyl, aryloxycarbonylC₁₋₅alkyl, heteroarylC₁₋₅alkyl where the heteroaryl contains 5 to 6 ring atoms;

15 R₆ is iodine, chlorine, or bromine; and pharmaceutically acceptable salts thereof.


24. The compound of claim 23 where R₁ is 4-fluorophenyl and R₂ is 3-pyrimidinyl or 4-pyridyl.

25. The compound of claim 24 where R₆ is iodine

26. The compound of claim 25 where R₃ is hydrogen, arylC₁₋₅alkyl or substituted arylC₁₋₅alkyl (where the aryl substituents are independently selected from one or more members of the group consisting of C₁₋₅alkyl, C₁₋₅alkoxy, halogen, amino, C₁₋₅alkylamino, and diC₁₋₅alkylamino).

27. A compound selected from the group consisting of, 4-(4-fluorophenyl)-2-iodo-1-(3-phenylpropyl)-5-(4-pyridinyl)imidazole, 4-(4-fluorophenyl)-2-bromo-1-(3-phenylpropyl)-5-(4-pyridinyl)imidazole, and 4-(4-fluorophenyl)-2-chloro-1-(3-phenylpropyl)-5-(4-pyridinyl)imidazole.

28. A method of preparing a compound of Formula I which comprises contacting a compound of Formula III



III


where

5 R_1 is phenyl, substituted phenyl (where the substituents are selected from the group consisting of C_{1-5} alkyl, halogen, nitro, trifluoromethyl, and nitrile), or heteroaryl where the heteroaryl contains 5 to 6 ring atoms;

10 R_2 is phenyl, substituted phenyl (where the substituents are selected from the group consisting of C_{1-5} alkyl, halogen, nitro, trifluoromethyl, and nitrile), heteroaryl where the heteroaryl contains 5 to 6 ring atoms and is optionally C_{1-4} alkyl substituted;

15 R_3 is hydrogen, SEM, C_{1-5} alkoxycarbonyl, aryloxycarbonyl, aryl C_{1-5} alkyloxycarbonyl, aryl C_{1-5} alkyl, substituted aryl C_{1-5} alkyl (where the aryl substituents are independently selected from one or more members of the group consisting of C_{1-5} alkyl, C_{1-5} alkoxy, halogen, amino, C_{1-5} alkylamino, and di C_{1-5} alkylamino), phthalimido C_{1-5} alkyl, amino C_{1-5} alkyl, diamino C_{1-5} alkyl, 20 succinimido C_{1-5} alkyl, C_{1-5} alkylcarbonyl, arylcarbonyl, C_{1-5} alkylcarbonyl C_{1-5} alkyl, aryloxycarbonyl C_{1-5} alkyl, heteroaryl C_{1-5} alkyl where the heteroaryl contains 5 to 6 ring atoms;

25 R_6 is iodine, chlorine, or bromine;
with a compound of Formula IV



IV

where

q is 0-9

30 and

X is hydrogen, C₁₋₅alkyl, substituted C₁₋₅alkyl, hydroxy, phenyl, substituted phenyl, amino, C₁₋₅alkylamino, nitrile, vinyl, ethynyl arylC₁₋₅alkyl, succinimido, phthalimidooxy and halogen.

5 in the presence of a palladium coupling agent, an organic base and a suitable solvent under reactions conditions which permit the preparation of a compound of Formula I.

10 29. The method of claim 28 where the palladium coupling agent is selected from the group consisting of bis(aceto)bis(triphenylphosphine)palladium (II), bis(triphenylphosphine)palladiumdichloride, bis(acetonitrile)chloronitropalladium (II), bis(acetonitrile)dichloronitropalladium (II), and bis(benzonitrile)dichloropalladium (II).

15 30. The method of claim 28 where the organic base is triethylamine.

31. The method of claim 28 where the compound of Formula II is 4-(4-fluorophenyl)-2-iodo-1-(3-phenylpropyl)-5-(4-pyridinyl)imidazole and the compound of Formula III is 3-butyne-1-ol.

20 32. The compound of claim 28 where the suitable solvent is methylene chloride and reaction conditions are refluxing methylene chloride.

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US 98/07910

A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 C07D401/04 C07D403/04 C07F7/08 A61K31/415 A61K31/44
A61K31/505

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C07D C07F A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 4 503 065 A (W.W. WILKERSON) 5 March 1985 see column 5 - column 6; claims	23-27
Y	WO 96 03387 A (G.D. SEARLE & CO.) 8 February 1996 see claims	1-32
Y	WO 93 14081 A (SMITHKLINE BEECHAM CORP.) 22 July 1993 cited in the application see claims	1-32

☐ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

30 June 1998

Date of mailing of the international search report

07.07.98

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Chouly, J

INTERNATIONAL SEARCH REPORT

national application No.

PCT/US 98/07910

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 18-22
because they relate to subject matter not required to be searched by this Authority, namely:
Remark: Although claims 18-22 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 98/07910

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
US 4503065	A	05-03-1985	NONE	
WO 9603387	A	08-02-1996	US 5620999 A	15-04-1997
			AU 3271695 A	22-02-1996
			CA 2195846 A	08-02-1996
			EP 0772601 A	14-05-1997
WO 9314081	A	22-07-1993	AU 3592393 A	03-08-1993
			BG 98902 A	30-06-1995
			BR 9305809 A	18-02-1997
			CA 2127876 A	22-07-1993
			CN 1083473 A	09-03-1994
			CZ 9401688 A	18-01-1995
			EP 0623126 A	09-11-1994
			FI 943319 A	12-09-1994
			HU 69714 A	28-09-1995
			JP 7503017 T	30-03-1995
			MX 9300141 A	29-07-1994
			NO 942618 A	30-08-1994
			NZ 249301 A	25-06-1996
			OA 9963 A	11-12-1995
			SK 83594 A	08-03-1995
			US 5686455 A	11-11-1997
			ZA 9300213 A	18-11-1993